Skip to main navigation
Skip to main content

 

Skip to content
  • HOME
  • ABOUT
    VBL
    • COMPANY OVERVIEW
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • ADVISORY BOARDS
  • CANCER
    PROGRAMS
    • CANCER PLATFORM & TECHNOLOGY
    • PUBLICATIONS
  • INFLAMMATION
    PROGRAMS
    • INFLAMMATORY PLATFORM
    • INFLAMMATORY PIPELINE
    • PUBLICATIONS
  • VB-600
    PLATFORM
    • OVERVIEW
    • TARGETING MOSPD2 FOR INFLAMMATION
    • TARGETING MOSPD2 FOR CANCER
    • PUBLICATIONS
  • PATIENTS &
    CAREGIVERS
    • CLINICAL TRIALS
    • COMPASSIONATE USE
  • INVESTOR
    RELATIONS
    • IR HOMEPAGE
    • PRESS RELEASES
    • EVENTS AND PRESENTATIONS
    • STOCK INFORMATION
    • ANALYST COVERAGE
    • CORPORATE GOVERNANCE
    • SEC FILINGS
    • INVESTOR FAQ & CONTACTS
About_VBL_2

Investor Relations

  • IR HOMEPAGE
  • PRESS RELEASES
  • EVENTS AND PRESENTATIONS
  • STOCK INFORMATION
  • ANALYST COVERAGE
  • SEC FILINGS
  • CORPORATE GOVERNANCE
  • INVESTOR FAQ & CONTACTS

Investor Relations

SEC Filing Details

Document Details

Form
SC 13G
Filing Date
Feb 17, 2015
Document Date
Feb 17, 2015
Form Description
A statement of beneficial ownership of common stock by certain persons
Filing Group
Other
Company
VBL Therapeutics
Issuer
Vascular Biogenics Ltd.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
  • Print Page
  • RSS
  • E-mail Alerts
  • Investor Contacts
Copyright © 2014 VBL All rights reserved
  • TERMS AND CONDITIONS
  • PRIVACY
  • CONTACT US
Design by: Berliner Design   |  Site by: foothold-systems
Print Friendly